Stock GLPG GALAPAGOS NV
Add to a list
To use this feature you must be a member
Log inSign up

Financials Galapagos NV

Equities

GLPG

BE0003818359

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam
Other stock markets
 11:35:09 2024-05-31 am EDT 		5-day change 1st Jan Change
25.74 EUR +1.82% Intraday chart for Galapagos NV +1.90% -30.41%
May. 31 Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment MT
May. 31 Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 12,060 5,264 3,227 2,722 2,438 1,696 - -
Enterprise Value (EV) 1 6,305 102.9 -1,450 2,722 -1,237 -1,672 -1,277 -861.4
P/E ratio 74.9 x -17.2 x -31.2 x -12.5 x 11.5 x -43.7 x -16.4 x -11.9 x
Yield - - - - - - - -
Capitalization / Revenue 13.5 x 9.93 x 6.65 x 5.39 x 3.11 x 5.42 x 5.61 x 5.79 x
EV / Revenue 7.04 x 0.19 x -2.99 x 5.39 x -1.58 x -5.34 x -4.22 x -2.94 x
EV / EBITDA 16.5 x -0.64 x 11.1 x -13.5 x - 16.2 x 8.88 x 6.18 x
EV / FCF 1.98 x -0.22 x 2.65 x - 2.91 x 5.52 x 2.57 x 1.27 x
FCF Yield 50.5% -457% 37.8% - 34.4% 18.1% 38.8% 78.9%
Price to Book 4.19 x 1.97 x 1.22 x - - 0.63 x 0.66 x 0.76 x
Nbr of stocks (in thousands) 64,667 65,412 65,553 65,836 65,897 65,897 - -
Reference price 2 186.5 80.48 49.22 41.35 36.99 25.74 25.74 25.74
Announcement Date 2/20/20 2/18/21 2/24/22 2/23/23 2/22/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 895.6 530.3 484.8 505.3 783.5 312.8 302.4 292.8
EBITDA 1 382.7 -160 -131 -202 - -102.9 -143.7 -139.4
EBIT 1 370.3 -178.6 -165.6 -267.5 129 -105.1 -154.4 -168.8
Operating Margin 41.35% -33.68% -34.15% -52.94% 16.46% -33.6% -51.07% -57.66%
Earnings before Tax (EBT) 1 150.1 -309.8 -123 -215.1 - 4.881 -46.01 -75.56
Net income 1 149.8 -305.4 -103.2 -218 211.7 -13.26 -71.48 -99.46
Net margin 16.73% -57.59% -21.29% -43.14% 27.02% -4.24% -23.64% -33.96%
EPS 2 2.490 -4.690 -1.580 -3.320 3.210 -0.5889 -1.571 -2.164
Free Cash Flow 1 3,186 -469.9 -547.7 - -425.2 -302.6 -495.9 -679.2
FCF margin 355.77% -88.6% -112.97% - -54.27% -96.75% -163.97% -231.95%
FCF Conversion (EBITDA) 832.48% - - - - - - -
FCF Conversion (Net income) 2,126.99% - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/20/20 2/18/21 2/24/22 2/23/23 2/22/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 143.4 144 137.7 274 136.2 95.12 178.9 150 120 334.7 62.43 60.6 60.93 64.68 55.85 55.85
EBITDA 15.79 - -44.04 - - -110.8 - - - - - - - - - -
EBIT 1 10.2 -21.1 -76.4 -97.5 -37.6 -132.5 21.97 -10.69 -30.23 148 -33.13 -29.36 -30.68 -27.49 -22.97 -23.21
Operating Margin 7.11% -14.65% -55.48% -35.58% -27.61% -139.26% 12.28% -7.13% -25.19% 44.21% -53.07% -48.46% -50.35% -42.5% -41.13% -41.56%
Earnings before Tax (EBT) 1 19.09 -11.6 -18.22 - 22.25 -207.6 23.46 18.46 25.73 - 22.94 -4.637 -7.706 -16.17 5.88 5.66
Net income 1 16.37 -13.3 -19 - 21.5 -207.2 23.21 5.101 25.83 157.6 90.22 -4.637 -7.706 -16.31 5.88 5.66
Net margin 11.41% -9.24% -13.8% - 15.79% -217.84% 12.97% 3.4% 21.52% 47.08% 144.51% -7.65% -12.65% -25.22% 10.53% 10.13%
EPS 2 0.2500 - -0.2900 - 0.3300 -3.160 - 0.0800 0.3900 2.390 - -0.2120 -0.1930 -0.2830 - -
Dividend per Share 2 - - - - - - - - - - - - - - - -
Announcement Date 2/24/22 5/5/22 8/4/22 8/4/22 11/3/22 2/23/23 5/4/23 8/3/23 11/2/23 2/22/24 5/2/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 5,755 5,161 4,676 - 3,675 3,368 2,973 2,558
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 3,186 -470 -548 - -425 -303 -496 -679
ROE (net income / shareholders' equity) 16.2% -11% -3.89% - 7.96% -1.42% -3.14% -4.35%
ROA (Net income/ Total Assets) 8.82% -5.18% -1.89% - 4.66% -3.68% -1.21% -3.78%
Assets 1 1,698 5,892 5,455 - 4,546 360.6 5,899 2,629
Book Value Per Share 2 44.50 40.80 40.30 - - 41.00 39.10 33.70
Cash Flow per Share 2 53.40 -6.530 -7.530 - - -2.300 -2.600 -4.100
Capex 1 22.4 42.5 54.2 - 19.3 29.8 37.4 31.9
Capex / Sales 2.5% 8.02% 11.18% - 2.46% 9.53% 12.36% 10.91%
Announcement Date 2/20/20 2/18/21 2/24/22 2/23/23 2/22/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Galapagos NV

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
25.74 EUR
Average target price
36.73 EUR
Spread / Average Target
+42.70%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GALAPAGOS NV Stock Galapagos NV
-30.41% 1.84B
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GLPG Stock
  4. Financials Galapagos NV